Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Assets
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Assets (ROA) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The investment activity ratios exhibit varied trends over the observed period. Generally, the ratios demonstrate a degree of stability with some fluctuations, particularly in equity turnover. A consistent downward trend is apparent in net fixed asset turnover, while total asset turnover shows a more complex pattern.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio generally decreased from 2.73 in March 2022 to 2.57 in December 2025. While fluctuations occurred throughout the period, the overall trajectory is downward. The ratio peaked at 2.89 in September 2022 before beginning a sustained decline. The most recent value suggests a potential stabilization, but remains below the initial value observed in March 2022.
- Total Asset Turnover
- Total asset turnover showed more variability. It increased from 0.51 in March 2022 to 0.56 in September 2022, remaining at that level through December 2022. A slight decrease to 0.54 was observed in March 2023, followed by a rise to 0.58 in March 2024. Subsequently, the ratio declined, reaching 0.47 in December 2025, representing the lowest value in the observed period. This indicates a decreasing efficiency in utilizing total assets to generate sales towards the end of the period.
- Equity Turnover
- Equity turnover experienced significant fluctuations. It remained relatively stable around 1.32 to 1.33 from March 2022 to December 2022. A notable increase to 1.51 was observed in June 2023, followed by a decline to 1.30 in June 2025. The ratio concluded the period at 1.24 in December 2025, indicating a reduced ability to generate sales from equity financing compared to the earlier part of the period. The volatility in this ratio is more pronounced than the other two ratios analyzed.
In summary, while total asset turnover showed some initial improvement, it ultimately declined. Net fixed asset turnover consistently decreased, and equity turnover exhibited substantial volatility with a downward trend in the latter half of the period. These trends suggest potential shifts in asset utilization and operational efficiency.
Net Fixed Asset Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Sales | |||||||||||||||||||||
| Property, plant and equipment, at cost, net of accumulated depreciation | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Net fixed asset turnover
= (SalesQ4 2025
+ SalesQ3 2025
+ SalesQ2 2025
+ SalesQ1 2025)
÷ Property, plant and equipment, at cost, net of accumulated depreciation
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The net fixed asset turnover ratio exhibits a generally stable pattern over the observed period, with some fluctuations. Initially, the ratio demonstrates an increasing trend from March 2022 to June 2022, peaking at 2.85, before declining slightly through December 2022 to 2.77. A period of relative stability follows through the first three quarters of 2023, hovering around 2.63. A gradual decline is then observed from December 2023 through September 2025, reaching a low of 2.51. A slight increase is noted in December 2025, bringing the ratio to 2.57.
- Overall Trend
- The ratio generally remains within a narrow band between 2.51 and 2.89 throughout the analyzed timeframe. While fluctuations occur, a significant or sustained directional shift is not apparent. The latter portion of the period shows a slight downward drift.
- Short-Term Fluctuations
- Quarterly variations are present. The ratio increased from the first to the second quarter of 2022, suggesting improved efficiency in asset utilization during that period. Similarly, a minor increase is observed between March and June 2024. Conversely, declines are seen between September and December 2022, and consistently from December 2023 through September 2025.
- Recent Performance
- The most recent quarters (September 2025 and December 2025) indicate a potential stabilization or slight recovery after the preceding decline. However, further observation is needed to confirm whether this represents a genuine trend reversal.
- Relationship to Sales
- Sales figures generally increased over the period, but not consistently enough to offset the increase in property, plant, and equipment, net of accumulated depreciation, which contributed to the observed fluctuations in the net fixed asset turnover ratio. The ratio’s decline suggests that the company is generating slightly less revenue per dollar invested in fixed assets in the later periods.
Total Asset Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Sales | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Total asset turnover
= (SalesQ4 2025
+ SalesQ3 2025
+ SalesQ2 2025
+ SalesQ1 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The total asset turnover ratio exhibits a generally stable pattern over the observed period, with some fluctuations. Initially, the ratio demonstrates an increasing trend from March 31, 2022, to September 30, 2022, followed by a period of relative stability before a slight decline towards the end of the analyzed timeframe.
- Initial Trend (Mar 31, 2022 – Sep 30, 2022)
- The total asset turnover ratio increased from 0.51 to 0.55. This suggests a growing efficiency in utilizing assets to generate sales during this period. The company was generating more sales per dollar of assets.
- Period of Stability (Dec 31, 2022 – Sep 30, 2023)
- From December 31, 2022, through September 30, 2023, the ratio remained relatively consistent, fluctuating between 0.54 and 0.56. This indicates a stable level of asset utilization during this timeframe.
- Subsequent Decline (Dec 31, 2023 – Dec 31, 2025)
- A gradual downward trend is observed from December 31, 2023, with the ratio decreasing from 0.55 to 0.47 by December 31, 2025. This suggests a decreasing efficiency in asset utilization, meaning more assets are required to generate the same level of sales. This decline warrants further investigation to determine the underlying causes.
- Peak and Trough Values
- The highest recorded ratio was 0.56, occurring in June 30, 2023, and September 30, 2023. The lowest recorded ratio was 0.47, occurring on December 31, 2025. These represent the periods of highest and lowest asset utilization efficiency, respectively.
- Sales and Asset Relationship
- While sales generally increased over the period, the decline in the total asset turnover ratio towards the end of the timeframe suggests that asset growth outpaced sales growth. This could be due to investments in new assets that have not yet translated into increased sales, or potentially, underperforming assets.
Overall, the observed trend indicates a period of stable asset utilization followed by a gradual decline. Continued monitoring of this ratio is recommended to assess whether the downward trend persists and to identify potential areas for improvement in asset management.
Equity Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Sales | |||||||||||||||||||||
| Total Merck & Co., Inc. stockholders’ equity | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Equity turnover
= (SalesQ4 2025
+ SalesQ3 2025
+ SalesQ2 2025
+ SalesQ1 2025)
÷ Total Merck & Co., Inc. stockholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The equity turnover ratio for the analyzed period demonstrates fluctuations, generally remaining within a relatively narrow range. An initial period of stability is followed by increased volatility and a subsequent decline towards the end of the observed timeframe.
- Overall Trend
- The equity turnover ratio began at 1.32 in the first quarter of 2022 and remained at that level through the second quarter. A slight increase to 1.33 was observed in the third quarter of 2022, before decreasing to 1.29 by the end of the year. The first half of 2023 saw a decrease to 1.24, followed by a notable increase to 1.51 in the second quarter. The ratio then moderated to 1.44 and further increased to 1.60 by the end of 2023. The beginning of 2024 showed a decrease to 1.52, followed by a gradual decline to 1.39 by the end of 2025.
- Peak and Trough
- The highest recorded equity turnover ratio was 1.60, occurring in the fourth quarter of 2023. The lowest ratio was 1.24, observed in both the first quarter of 2023 and the fourth quarter of 2025.
- Recent Performance
- From the fourth quarter of 2023 to the fourth quarter of 2025, a consistent downward trend is apparent. The ratio decreased from 1.60 to 1.24 over this period, indicating a diminishing ability to generate sales relative to the level of stockholders’ equity. This decline occurred despite fluctuations in sales figures.
- Relationship to Sales
- While sales experienced fluctuations throughout the period, the equity turnover ratio did not consistently mirror these changes. For example, sales decreased from the first to the second quarter of 2022, but the equity turnover ratio remained constant. Similarly, a substantial increase in sales in the third quarter of 2025 did not translate into a corresponding increase in the equity turnover ratio, suggesting factors beyond sales volume are influencing the ratio’s performance.